Modern Approaches to Treating Rosacea in 2025
At the 2025 ODAC Dermatology Conference, renowned dermatologist and conference co-chair Adam Friedman, MD, delivered an insightful lecture, How I Treat Rosacea in 2025. He explored the latest advancements in managing one of dermatology’s most prevalent conditions, highlighting key triggers, associated comorbidities, and evolving treatment strategies. With global rosacea prevalence reported as hi …
At the 2025 ODAC Dermatology Conference, renowned dermatologist and conference co-chair Adam Friedman, MD, delivered an insightful lecture, How I Treat Rosacea in 2025. He explored the latest advancements in managing one of dermatology’s most prevalent conditions, highlighting key triggers, associated comorbidities, and evolving treatment strategies. With global rosacea prevalence reported as hi … Continue reading "Modern Approaches to Treating Rosacea in 2025"
Dermatologists need to be more visible in treating chronic spontaneous urticaria (CSU), says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared what to consider when approaching a hive or hive-like patient. Hear the burden that patients with CSU face. Find out the first-line tr … 
Hair loss is a broad category that can be difficult for dermatology clinicians to manage. Having a scripted or algorithmic approach to alopecia consults can decrease clinician anxiety, says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared his approach for evaluating alopecia … 
There’s never a wrong time to address photoprotection – including sunscreen use – with your patients, says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared some of the challenges in getting patients to properly and consistently use sunscreen. Learn Dr. Friedman’s appr … 
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis … 